Table 1. Variables included in RELESSER

|  |  |
| --- | --- |
| *Demographics* | Gender, age, race  |
| *Chronological data* | Start dates and diagnosis of SLE and its major events  |
| Background  | Personal or family history of autoimmune disease  |
| *Vital status* | Exitus, cause of death  |
| *SLE Criteria* | ACR classification criteria 1997  |
| Manifestations accumulated  | According to the ACR glossaries for SLE classification criteria, SLEDAI, BILAG and SLICC/ACR DI  |
| Uncommon manifestations  | Manifestations prevalence <1%  |
| Status of disease  | SELENA-SLEDAI Activity Index (current and cumulative), damage (SLICC/ACR DI) and severity (IGK)  |
| *Comorbidity* | Diabetes, dyslipidemia, hypertension, cardiovascular events, thyroid disease, malignancies, osteoporosis (WHO criteria), depression, fibromyalgia (ACR criteria), serious infections, Charlson index  |
| Laboratory  | Laboratory tests including immunologic parameters  |
| *Treatments* | Current and accumulated pharmacological and therapeutic procedures, cause of discontinuation as per case (clinical problem solved, ineffectiveness, or other adverse reaction)  |
| Associated autoimmune pathologies  | Antiphospholipid síndrome defined according to the Sidney criteria, Sjögren's syndrome in the presence of compatible sicca syndrome and positive Schirmer test, or biopsy/salivary gland scintigraphy, mixed connective tissue disease defined according to the criteria proposed by Alarcon-Segovia  |

ACR: American College of Rheumatology; BILAG: British Isles Lupus Assessment Group; IGK: Katz severity index, SLE: systemic lupus erythematosus; WHO: World Health Organization; SELENA-SLEDAI: Safety of Estrogens in Systemic Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index, SLICC/ACR DI: Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index.

In italics, variables considered “essential” for the record.

Table 2. Clinical associations between lupus nephritis and other SLE manifestations.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | LN-positiven=1,092 | LN-negativen=2,258 | Crude OR | CI (95%) | p-value | Adjusted OR& | CI (95%) | p-value |
| Female  |  |  | 0.49  | 0.39-0.61 | p<.001 | - | - | - |
| Age of disease onset (years) |  |  | 0.96 | 0.96-0.97 | p<.001 | - | - | - |
| Duration of the disease (months) |  |  | 1.00 | 1.00-1.00 | p<.001 | - | - | - |
| Photosensitivity | 1,353 (61.4) | 594 (56.6) | 0.82 | 0.71-0.95 | p=.010 | 0.75 | 0.64-0.88 | p<.001 |
| Malar rash | 1,151 (51.6) | 673 (62.5) | 1.56 | 1.35-1.81 | p<.001 | 1.26 | 1.07-1.48 | p=.005 |
| Pleuritis | 416 (18.8) | 340 (31.7) | 2.00 | 1.70-2.37 | p<.001 | 1.83 | 1.53-2.18 | p<.001 |
| Pericarditis | 279 (12.6) | 248 (23.4) | 2.10  | 1.75-2.52 | p<.001 | 1.85 | 1.52-2.25 | p<.001 |
| Alveolointerstitial disease | 74 (3.3) | 59 (5.5) | 1.70 | 1.20-2.41 | p=.003 | 1.85 | 1.27-2.70 | p=.001 |
| Alveolar bleeding | 12 (0.5) | 20 (1.9) | 3.51 | 1.71-7.21 | p=.001 | 4.07 | 1.90 -8.72 | p<.001 |
| Seizures | 85 (3.8) | 83 (7.7) | 2.12 | 1.55-2.89 | p<.001 | 1.59 | 1.14-2.22 | p=.006 |
| Psychosis | 42 (3.9) | 58 (2.6) | 1.52 | 1.01-2.27 | p=0.04 | 1.22 | 0.79-1.89 | p=.369 |
| Haemolytic anemia | 145 (6.6) | 153 (14.5) | 2.41 | 1.90-3.07 | p<.001 | 2.40 | 1.85-3.11 | p<.001 |
| Leukopenia | 1,263(57.1) | 700 (65.7) | 1.44 | 1.24-1.68 | p<.001 | 1.36 | 1.16-1.60 | p=.001 |
| Lymphopenia | 1,131 (51.5) | 632 (59.5) | 1.38 | 1.19-1.60 | p<.001 | 1.37 | 1.17-1.60 | p<.001 |
| Thrombocytopenia | 453 (20.8)  | 294 (28.3)  | 1.50 | 1.27-1.78 | p<.001 | 1.35 | 1.13-1.62 | p=.001 |
| Anti-dsDNA | 1,458 (65.9) | 961 (90.3) | 4.81 | 3.86-6.01 | p<.001 | 4.23 | 3.36-5.33 | p<.001 |
| Anti-Sm ^ | 380 (17.7) | 287 (27.7) | 1.78 | 1.50-2.13 | p<.001 | 1.69 | 1.40-2.04 | p<.001 |
| Anti-RNP | 529 (24.1) | 293 (28.0) | 1.23 | 1.04-1.45 | p=.016 | 1.13 | 0.95-1.35 | p=.170 |
| Lupus anticoagulant | 353 (22.2) | 232 (27.0) | 1.30 | 1.07-1.57 | p=.008 | 1.20 | 0.98-1.48 | p=.078 |
| Antiphospholipid síndrome | 272 (12.2) | 194 (18.0) | 1.58 | 1.29-1.93 | p<.001 | 1.45 | 1.17-1.80 | p=.001 |
| Low complement levels | 1,590 (71.8) | 984 (92.0) | 4.51 | 3.55-5.72 | p<.001 | 3.58 | 2.79-4.60 | p<.001 |
| Arterial thrombosis | 85 (3.8) | 76 (7.0) | 1.91 | 1.39-2.63 | p<.001 | 1.92 | 1.36-2.72 | p<.001 |
| Venous thrombosis | 74 (3.3) | 60 (5.6) | 1.73 | 1.22-2.45 | p=.002 | 1.51 | 1.03-2.21 | p=.036 |
| Avascular osteonecrosis | 56 (2.5) | 83 (7.7) | 3.27 | 2.31-4.63 | p<.001 | 2.23 | 1.53-3.25 | p<.001 |
| Gonadal failure | 16 (2.3) | 71 (24.9) | 14.33 | 8.16-25.18 | p<.001 | 6.66 | 3.63-12.22 | p<.001 |
| Preeclampsia# | 53 (2.7) | 39 (4.3) | 1.65 | 1.09-2.52 | p=.019 | 1.46 | 0.93-2.29 | p=.103 |
| Pregnancies# | 1,351 (67.9) | 524 (58.2) | 0.66 | 0.56-0.77 | p<.001 | 0.75 | 0.62-0.89 | p=.001 |
| Term pregnancies# | 1,231 (61.9) | 452 (50.2) | 0.62 | 0.53-0.73 | p<.001 | 0.72 | 0.61-0.86 | p<.001 |
| Cardiomyopathy | 44 (2.0) | 47 (4.4) | 2.27 | 1.49-3.45 | p<.001 | 2.74 | 1.73-3.36 | p<.001 |
| Valvular disease | 105 (4.8) | 99 (9.2) | 2.04 | 1.53-2.71 | p<.001 | 2.14 | 1.57-2.93 | p<.001 |
| Stroke | 89 (4.0) | 87 (8.1) | 2.12 | 1.56-2.87 | p<.001 | 2.17 | 1.56-3.01 | p<.001 |
| Death | 92 (4.5) | 101 (10.0) | 2.38 | 1.77-3.19 | p<.001 | 3.29 | 2.37-4.57 | p<.001 |

& Adjusted by the age at the onset of the disease (years), sex and duration of the disease (months).

^ Adjusted by the age at the onset of the disease (years), sex and ethnicity.

# Adjusted by the age at the onset of the disease (years) and duration of the disease (months).